EyePoint Pharmaceuticals, Inc. Blog | Talkmarkets | Page 1
No data available
No data available

People who follow this stock (3)

Latest Posts

About This Stock More About This Stock
Week In Review: Sorrento Therapeutics Fights $933 Million Take-Private Bid
Article By: ChinaBio® Today
Saturday, February 1, 2020 5:24 PM EST
Sorrento Therapeutics, a San Diego-Nanjing-Suzhou biopharma, rejected a $7 per share take-private offer from an unnamed PE company that valued the company at $933 million. Sorrento reported a loss of $57 million over the last 12 months.
In this article: AZN, ROG, SRNE, DMPI, EYPT
Read
Week In Review: BioMérieux Acquires Majority Stake In China Diagnostics Company For $114 Million
Article By: ChinaBio® Today
Saturday, November 10, 2018 4:08 PM EST
French in vitro diagnostics company, bioMérieux (Paris: BIM), acquired a majority stake in Suzhou Hybiome Biomedical Engineering for $114 million. Hybiome specializes in automated immunoassay tests.
In this article: ASND, EYPT
Read
EyePoint Pharmaceuticals Q4 Earnings Preview: What To Know Ahead Of The Release
Article By: Zacks Investment Research
Monday, September 3, 2018 2:00 PM EST
Wall Street expects a year-over-year increase in earnings on lower revenues when EyePoint Pharmaceuticals reports results for the quarter ended June 2018.
In this article: EYPT
Read

PARTNER HEADLINES

Latest Tweets for $EYPT

No tweets yet!

$EYPT

Global Investing: Oh Cannabis
Howie Sandberg 10/18/2018 2:15:42 PM

Nice, hard to find any info on $EYPT, which I've been interested in for a while.

1 to 1 of 1 comments